ArticleJACC. Advances2026

Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.

Ahmed Y Azzam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.